Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)

• Published in: Hepatology international 2022-02, Vol.16 (1), p.59-67
• Main Authors: Huang, Jee-Fu, Hsieh, Ming-Yen, Wei, Yu-Ju, Hung, Jen-Yu, Huang, Hsuan-Ti, Huang, Ching-I, Yeh, Ming-Lun, Huang, Chung-Feng, Jang, Tyng-Yuan, Hsu, Po-Yao, Liang, Po-Cheng, Dai, Chia-Yen, Lin, Zu-Yau, Yu, Ming-Lung, Chuang, Wan-Long
• Format: Article
• Language: English
• Subjects: Antiviral agents; Antiviral Agents - therapeutic use; Cancer; Chemotherapy; Colorectal Surgery; Confidence intervals; Hepacivirus; Hepatitis; Hepatitis C; Hepatitis C - drug therapy; Hepatitis C - epidemiology; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - epidemiology; Hepatology; Hospitals; Humans; Medicine; Medicine & Public Health; Occupational safety; Original; Original Article; Patient safety; Patients; Personnel; Pilot Projects; Surgery; Surveillance; Viruses
• ISSN: 1936-0533; 1936-0541
• DOI: 10.1007/s12072-021-10275-7

Key points Question Is hepatitis C virus (HCV) micro-elimination achievable at the hospital level with the structured strategies? Findings The multidirectional program included the HCV reflex test for hospital personnel, outpatient surveillance, a call-back system, and surveillance of cancer patients prior to chemotherapy. Through the plans of the study, 97.8% of the HCV-viremic patients successfully received linkage-to-treat. The results of each strategy sufficiently met the 2030 elimination goal by the World Health Organization (WHO). Meaning HCV micro-elimination is achievable at the hospital level based on patient safety, staff occupational safety and infection control. Background and aims Scarce data are available on in-hospital hepatitis C virus (HCV) micro-elimination strategies. This pilot study was prospectively conducted to assess the outcomes of HCV in-hospital micro-elimination program (HCV-HELP) in a single center in Taiwan. Methods The study included the HCV reflex test for plans A (hospital personnel), B (outpatient surveillance), C (a call-back system for anti-HCV+ patients), and D (surveillance of cancer patients prior to chemotherapy). The primary outcome measurement was that > 80% of eligible patients were enrolled in linkage-to-treat; the secondary outcome measurement was the surveillance efficacy. Results We recruited 930, 6072, 2376 and 233 participants into plans A, B, C, and D, respectively, from Oct 2020 to May 2021. The anti-HCV-seropositivity prevalences were 0.22% for plan A, 4.3% for B, and 3.9% for D. Two staff members were identified as HCV-viremic in plan A; these staff members successfully achieved a sustained virological response (SVR). We identified 39, 95 and 2 HCV-viremic patients in plans B, C, and D, respectively. Of these 138 HCV-viremic patients, 135 (97.8%) received direct-acting antiviral therapy, and 134 achieved SVR. Two 4-month phases were stratified to compare efficacies in the liver clinic. In the late phase, the adjusted number of HCV-viremic patients was 4.36/10,000 outpatient visits (90/200,689), which was 3.18-fold higher than that of the early phase (1.37/10,000 outpatient visits [30/212,658], odds ratio 3.18; 95% confidence interval 2.10–4.81, p